JP2006523432A5 - - Google Patents

Info

Publication number

JP2006523432A5

JP2006523432A5 JP2004552655A JP2004552655A JP2006523432A5 JP 2006523432 A5 JP2006523432 A5 JP 2006523432A5 JP 2004552655 A JP2004552655 A JP 2004552655A JP 2004552655 A JP2004552655 A JP 2004552655A JP 2006523432 A5 JP2006523432 A5 JP 2006523432A5

Authority

JP

Japan

Prior art keywords

protein

soluble

amino acid

cells

nucleic acid

Prior art date

2003-11-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102100035793 CD83 antigen Human genes 0.000 claims 36
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 36
• 125000000539 amino acid group Chemical group 0.000 claims 14
• 108020004707 nucleic acids Proteins 0.000 claims 12
• 102000039446 nucleic acids Human genes 0.000 claims 12
• 150000007523 nucleic acids Chemical class 0.000 claims 12
• 230000024932 T cell mediated immunity Effects 0.000 claims 8
• 210000001744 T-lymphocyte Anatomy 0.000 claims 8
• 210000003719 b-lymphocyte Anatomy 0.000 claims 8
• 210000004443 dendritic cell Anatomy 0.000 claims 8
• 230000004064 dysfunction Effects 0.000 claims 8
• 238000011282 treatment Methods 0.000 claims 8
• 239000013598 vector Substances 0.000 claims 8
• 201000010099 disease Diseases 0.000 claims 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
• 239000000178 monomer Substances 0.000 claims 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims 5
• 239000003814 drug Substances 0.000 claims 5
• 238000004519 manufacturing process Methods 0.000 claims 5
• 238000000034 method Methods 0.000 claims 5
• 230000002265 prevention Effects 0.000 claims 5
• 235000018102 proteins Nutrition 0.000 claims 5
• 102000004169 proteins and genes Human genes 0.000 claims 5
• 108090000623 proteins and genes Proteins 0.000 claims 5
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 4
• 235000001014 amino acid Nutrition 0.000 claims 4
• 150000001413 amino acids Chemical class 0.000 claims 4
• 210000004027 cell Anatomy 0.000 claims 4
• 239000013604 expression vector Substances 0.000 claims 4
• 239000012634 fragment Substances 0.000 claims 4
• 238000003259 recombinant expression Methods 0.000 claims 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
• 208000030507 AIDS Diseases 0.000 claims 2
• 208000023275 Autoimmune disease Diseases 0.000 claims 2
• 208000011231 Crohn disease Diseases 0.000 claims 2
• 206010020751 Hypersensitivity Diseases 0.000 claims 2
• 206010033799 Paralysis Diseases 0.000 claims 2
• 201000004681 Psoriasis Diseases 0.000 claims 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
• 206010047115 Vasculitis Diseases 0.000 claims 2
• 208000026935 allergic disease Diseases 0.000 claims 2
• 230000007815 allergy Effects 0.000 claims 2
• 208000006673 asthma Diseases 0.000 claims 2
• 230000001684 chronic effect Effects 0.000 claims 2
• 206010009887 colitis Diseases 0.000 claims 2
• 235000018417 cysteine Nutrition 0.000 claims 2
• 239000000539 dimer Substances 0.000 claims 2
• 230000003834 intracellular effect Effects 0.000 claims 2
• 201000006417 multiple sclerosis Diseases 0.000 claims 2
• 210000000056 organ Anatomy 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 238000011321 prophylaxis Methods 0.000 claims 2
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
• 208000017520 skin disease Diseases 0.000 claims 2
• 208000011580 syndromic disease Diseases 0.000 claims 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
• 206010009900 Colitis ulcerative Diseases 0.000 claims 1
• 239000004471 Glycine Substances 0.000 claims 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 206010028372 Muscular weakness Diseases 0.000 claims 1
• 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 1
• 206010052779 Transplant rejections Diseases 0.000 claims 1
• 208000025865 Ulcer Diseases 0.000 claims 1
• 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
• 235000004279 alanine Nutrition 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 230000001363 autoimmune Effects 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
• 230000003828 downregulation Effects 0.000 claims 1
• 239000000710 homodimer Substances 0.000 claims 1
• 230000002757 inflammatory effect Effects 0.000 claims 1
• 230000036473 myasthenia Effects 0.000 claims 1
• 206010028417 myasthenia gravis Diseases 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1
• 239000013636 protein dimer Substances 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 238000007910 systemic administration Methods 0.000 claims 1